International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment, Ann Oncol, vol.22, pp.515-538, 2011. ,
Surgical aspects of inflammatory breast cancer, Breast Dis, vol.22, pp.67-73, 2005. ,
Inflammatory breast cancer: the disease, the biology, the treatment, CA Cancer J Clin, vol.60, pp.351-75, 2010. ,
Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer, Mol Oncol, vol.9, pp.1155-68, 2015. ,
Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease, Mol Oncol, vol.9, pp.1218-1251, 2015. ,
Overcoming radiation resistance in inflammatory breast cancer, Cancer, vol.116, pp.2840-2845, 2010. ,
Neoadjuvant treatment of breast cancer-clinical and research perspective, Breast, vol.24, pp.73-77, 2015. ,
Current and future role of neoadjuvant therapy for breast cancer, Breast, vol.23, pp.526-563, 2014. ,
Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer, Ann Surg Oncol, vol.19, pp.1508-1524, 2012. ,
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis, Lancet, vol.384, pp.164-72, 2014. ,
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update, J Clin Oncol, vol.24, pp.1940-1949, 2006. ,
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives, Ann Oncol, vol.18, pp.1927-1961, 2006. ,
Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily ,
SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer, Breast Cancer Res Treat, vol.158, pp.485-95, 2016. ,
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort, Lancet, vol.375, pp.377-84, 2010. ,
Pathological complete response and accelerated drug approval in early breast cancer, N Engl J Med, vol.366, pp.2438-2479, 2012. ,
Inflammatory carcinomas of the breast: a clinical, pathological, or a clinical and pathological definition?, Int J Cancer, vol.62, pp.382-387, 1995. ,
The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer, Semin Oncol, vol.26, pp.24-31, 1999. ,
Paclitaxel in the multimodality treatment for inflammatory breast carcinoma, Cancer, vol.92, pp.1775-82, 2001. ,
First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial), Br J Cancer, vol.81, pp.449-56, 1999. ,
UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer, Ann Oncol, vol.26, pp.1692-1699, 2015. ,
,
, Dose-intensified chemotherapy and additional Docetaxel may improve inflammatory breast cancer patients outcome over two decades: results from Institut Curie protocols 1977?_"1987 and two consecutive French multicenter trials Pegase 02 (1995?_"96) and Pegase 05 (1997?_"99), ASCO Annu Meet Proc, vol.22, p.848, 2004.
Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor-and HER2-defined subtypes, Ann Oncol, vol.25, pp.384-91, 2014. ,
Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study, Cancer, vol.117, pp.1819-1845, 2011. ,
The role of locoregional therapy in inflammatory breast cancer, Semin Oncol, vol.35, pp.78-86, 2008. ,
Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy, J Clin Oncol, vol.22, pp.4067-74, 2004. ,
Inflammatory breast cancer management in the national comprehensive cancer network: the disease, recurrence pattern, and outcome, Clin Breast Cancer, vol.15, pp.1-7, 2015. ,
Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study, Br J Cancer, vol.95, pp.1005-1017, 2006. ,
Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups, J Clin Oncol, vol.29, pp.3351-3358, 2011. ,
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy, Lancet Oncol, vol.13, pp.135-179, 2012. ,
,
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial, Lancet Oncol, vol.15, pp.747-56, 2014. ,
Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, Lancet Oncol, vol.16, pp.656-66, 2015. ,
Nabpaclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, Lancet Oncol, vol.17, pp.345-56, 2016. ,
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial, Lancet Oncol, vol.13, pp.25-32, 2012. ,
Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data, J Clin Oncol, vol.28, pp.83-91, 2010. ,
Capecitabine in addition to anthracycline-and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study, J Clin Oncol, vol.28, pp.2015-2038, 2010. ,
Inflammatory breast cancer: a review, J Clin Oncol, vol.10, pp.1014-1038, 1992. ,
Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival, Ann Oncol, vol.25, pp.358-65, 2013. ,
Inflammatory breast cancer: a distinct clinicopathological entity transcending histological distinction, PLoS One, vol.11, p.145534, 2016. ,
Genomic profiling of inflammatory breast cancer: a review, Breast, vol.23, pp.538-583, 2014. ,
Gene expression profiling of inflammatory breast cancer, Cancer, vol.116, pp.2783-93, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-01612154
Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes, J Clin Oncol, vol.23, pp.41-49, 2005. ,
Supervised risk predictor of breast cancer based on intrinsic subtypes, J Clin Oncol, vol.27, pp.1160-1167, 2009. ,
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer, Ann Oncol, vol.24, pp.2206-2229, 2013. ,